Citations

Clear

3942 citation(s) found for "To, Van".

Physical activity patterns and clusters in 1001 patients with COPD
Mesquita, Rafael , Spina, Gabriele , Pitta, Fábio , Donaire-González, David , Deering, Brenda, Patel, Mehul S. , Gestel, Arnoldus JR van, Zogg, Stefanie, Abascal-Bolado, Beatriz , Vagaggini, Barbara, Jenkins, Sue, Romme, Elisabeth APM, Kon, Samantha S.C. , Albert, Paul , Waschki, Benjamin , Shrikrishna, Dinesh , Singh, Sally , Hopkinson, Nicholas S , Miedinger, David , Benzo, Roberto P. , Maltais, François , Paggiaro, Pierluigi, McKeough, Zoe , Polkey, Michael I. , Hill, Kylie , Man, William D‐C , Clarenbach, Christian F. , Hernandes, Nídia Aparecida , Savi, Daniela , Wootton, Sally , Furlanetto, Karina Couto , Ng, Li Whye Cindy, Vaes, Anouk W, Jenkins, Christine , Eastwood, Peter R. , Jarreta, Diana, Kirsten, Anne, Brooks, Dina , Hillman, David R. , Sant’Anna, Thaís , Meijer, Kenneth , Dürr, Selina , Rutten, Erica P.A., Kohler, Malcolm , Probst, Vanessa S. , Tal‐Singer, Ruth , Gil, Esther García, Brinker, Albertus C. den , Leuppi, Jörg D. , Costello, Richard W. , Gramm, Marco, Goldstein, Roger , Groenen, Miriam , Magnussen, H, Wouters, Emiel F.�M. , ZuWallack, Richard , Watz, Henrik, Spruit, Martijn A. , Mitchell, Katy , Alison, Jennifer Ailsey , Gagnon, Philippe , Vagaggini, Barbara, García‐Aymerich, Judith , Paggiaro, Pierluigi , Vaes, Anouk W, Kirsten, Anne‐Marie , Calverley, Peter M.A. , Smeenk, Frank W.J.M. , Amft, Oliver , Costello, Richard W , Tal-Singer, Ruth

Mayo Clinic

Chronic Respiratory Disease | February 24, 2017 | Volume: 14 | Issue: 3 | Pages: 256-269

10.1177/1479972316687207 | PMID 28774199 Get It

We described physical activity measures and hourly patterns in patients with chronic obstructive pulmonary disease (COPD) after stratification for generic and COPD-specific characteristics and, based on multiple physical activity measures, we identified clusters of patients. In total, 1001 patients with COPD (65% men; age, 67 years; forced expiratory volume in the first second [FEV 1 ], 49% predicted) were studied cross-sectionally. Demographics, anthropometrics, lung function and clinical data were assessed. Daily physical activity measures and hourly patterns were analysed based on data from a multisensor armband. Principal component analysis (PCA) and cluster analysis were applied to physical activity measures to identify clusters. Age, body mass index (BMI), dyspnoea grade and ADO index (including age, dyspnoea and airflow obstruction) were associated with physical activity measures and hourly patterns. Five clusters were identified based on three PCA components, which accounted for 60% of variance of the data. Importantly, couch potatoes (i.e. the most inactive cluster) were characterised by higher BMI, lower FEV 1 , worse dyspnoea and higher ADO index compared to other clusters ( p < 0.05 for all). Daily physical activity measures and hourly patterns are heterogeneous in COPD. Clusters of patients were identified solely based on physical activity data. These findings may be useful to develop interventions aiming to promote physical activity in COPD.
Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after sta
Grothey, Axel, Sobrero, Alberto , Lenz, Heinz‐Josef , Cihon, Frank, Wagner, Andrea, Siena, Salvatore , Falcone, Alfredo , Ychou, Marc , Yoshino, Takayuki , Wagner, Andrea, Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 30 | Issue: 4_suppl | Pages: LBA385-LBA385

10.1200/jco.2012.30.4_suppl.lba385 Get It

LBA385 Background: Regorafenib (BAY 73-4506) is an oral multikinase inhibitor of a broad range of angiogenic, oncogenic, and stromal kinases. The phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in pts with mCRC who had progressed after all approved standard therapies. Methods: Enrollment criteria included documented mCRC and progression during or ≤3 months after last standard therapy. Pts were randomized 2:1 to receive regorafenib (160 mg od po, 3 weeks on/1 week off) plus BSC, or placebo (PL) plus BSC. Pts continued on treatment until progression, death, or unacceptable toxicity. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), safety, and quality of life. Results: From May 2010 to March 2011, 760 pts were randomized (regorafenib: 505; PL: 255). Baseline characteristics were balanced between two arms. Preliminary results are available from a pre-planned formal interim analysis. The estimated hazard ratio (HR) for OS was 0.773 (95% CI: 0.635, 0.941; 1-sided p=0.0051). Median OS was 6.4 mos (95% CI: 5.9, 7.3) for regorafenib and 5.0 mos (95% CI: 4.4, 5.8) for PL. The estimated HR for PFS was 0.493 (95% CI: 0.418, 0.581; 1-sided p < 0.000001). Median PFS was 1.9 mos (95% CI: 1.88, 2.17) for regorafenib and 1.7 mos (95% CI: 1.68, 1.74) for PL. ORR was 1.6% for regorafenib and 0.4% for PL. DCR was 44% for regorafenib and 15% for PL (p < 0.000001). Since the prespecified OS efficacy boundary was crossed (nominal α: 0.0093), the Data Monitoring Committee recommended to unblind the study and pts on PL were allowed to cross over to regorafenib. The most frequent grade 3+ AEs in the regorafenib arm were hand-foot skin reaction (17%), fatigue (15%), diarrhea (8%), hyperbilirubinemia (8%), and hypertension (7%). Updated results will be presented. Conclusions: Statistically significant benefit in OS and PFS was observed for regorafenib over PL in pts with mCRC who have failed all approved standard therapies. No new or unexpected safety signal was found.
Effect of online education on use of molecular markers to guide treatment selection for advanced gastric or gastroesophageal (GE) cancer.
Obholz, Kevin L, Bowser, Andrew, Mortimer, Jim, Wasserstrom, June, Cutsem, Eric Van , Press, Michael F. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 30 | Issue: 4_suppl | Pages: 111-111

10.1200/jco.2012.30.4_suppl.111 Get It

111 Background: Trastuzumab in combination with chemotherapy is recommended for advanced gastric cancer positive for human epidermal growth factor receptor 2 (HER2) overexpression. Despite this recommendation, an informal pilot survey suggested that many oncologists do not include HER2 testing as part of routine practice to identify patients most likely to benefit from adding trastuzumab to chemotherapy. Methods: An interactive online educational activity was developed to provide expert guidance on HER2 testing and use of HER2-targeted agents in gastric or GE cancer. Pre- and post-education surveys were administered as part of the activity to measure changes in participant competence. In addition, 3 months after completing the educational activity, participants were sent another follow-up survey by email to assess changes in practice. Results: To date, pre-and post-education surveys have been obtained for 122 oncologists and 3-month follow-up surveys obtained from 14 oncologists. In the pre-education survey, only 46% said they were testing all of their patients with advanced gastric or GE cancer for HER2 overexpression. However, immediately after participating in the educational intervention, this proportion increased to 93%. Importantly, a follow-up survey indicated that HER2 testing of all patients with advanced gastric or GE cancer was now part of routine practice for 79% of those surveyed. A final analysis of pre- and post-education and 3-month follow-up surveys will be presented. Conclusions: Expert guidance on HER2 testing and use of HER2-targeted agents in gastric or GE cancer provided through an interactive online educational intervention substantially improved oncologist competence and practice patterns.
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).
Shah, Manali, Ito, Tetsuhide , Wolin, Edward M. , Sachs, C., Winkler, Robert , Lincy, Jeremie , Hobday, Timothy J. , Shah, M. H., Lombard‐Bohas, Catherine , Cutsem, Eric Van , Yao, James C.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 4_suppl | Pages: 158-158

10.1200/jco.2011.29.4_suppl.158 Get It

158 Background: There is an unmet medical need for effective treatments for patients with advanced pNET. Systemic therapies for advanced pNET are limited both by toxicity and efficacy. Everolimus, an oral mTOR inhibitor, has shown promising antitumor activity in 2 phase II studies, leading to further investigation in the largest phase III randomized controlled trial completed in pNET patients. Methods: Patients with advanced low- or intermediate-grade pNET were randomly assigned to everolimus 10 mg/d orally + best supportive care (BSC; n = 207) or placebo + BSC (n = 203). Long-acting somatostatin analogs (SSAs) were permitted as BSC during the study. The primary endpoint was progression free survival (PFS). At progression (RECIST), patients could be unblinded and those randomly assigned to placebo were offered open-label everolimus. Results: Compared with placebo, everolimus reduced the risk of progression by 65% and increased median PFS by more than 6 months, from 4.6 to 11.0 months (HR = 0.35; 95% CI: 0.27-0.45; p < 0.0001), by investigator review (primary endpoint). Median PFS by central review was consistent (HR = 0.34; 95% CI: 0.26 to 0.44; p < 0.001] in favor of everolimus. Eighteen-month PFS estimates were 34% for everolimus (95% CI: 26-43) vs 9% (95% CI: 4-16) for placebo. Everolimus demonstrated a significant PFS benefit across all patient subgroups according to baseline characteristics and prior SSA use. Prior SSA use was 49% in the everolimus arm and 50% in the placebo arm. Updated analyses of the impact of concomitant SSA will be reported. The most common drug-related adverse events were stomatitis, rash, diarrhea, fatigue, and infections (primarily upper respiratory); most were grade 1 or 2. Stomatitis (6.9% vs 0%), anemia (6% vs 0%), and hyperglycemia (5% vs 2%) were the most common grade 3-4 events. Conclusions: Everolimus significantly prolonged PFS compared with placebo in patients with advanced pNET in this large phase III clinical trial. This benefit was seen across all patient subgroups. Treatment resulted in a significant 6.4-month prolongation in median PFS. Everolimus had an acceptable and predictable safety profile. [Table: see text]
Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders
Wolff, Markus , Johannesen, Katrine M. , Hedrich, Ulrike B. S. , Masnada, Silvia , Rubboli, Guido , Gardella, Elena , Lesca, Gaëtan , Ville, Dorothée , Milh, Mathieu , Villard, Laurent , Afenjar, Alexandra , Chantot‐Bastaraud, Sandra , Mignot, Cyril , Lardennois, Caroline, Nava, Caroline , Schwarz, Niklas , Gérard, Marion , Perrin, Laurence, Doummar, Diane , Miranda, María J., Hempel, Maja , Brilstra, Eva H. , Knoers, Nine, Verbeek, Nienke E., Kempen, Marjan van, Braun, Kees P. J. , Mancini, Grazia M.S. , Biskup, Saskia, Hörtnagel, Konstanze , Döcker, Miriam, Bast, Thomas , Loddenkemper, Tobias , Baumeister, Friedrich, Fazeli, Walid , Striano, Pasquale, Dilena, Robertino , Fontana, Elena , Zara, Federico , Kurlemann, Gerhard, Klepper, Joerg , Thoene, Jess G. , Arndt, Daniel H. , Deconinck, Nicolas , Schmitt‐Mechelke, Thomas , Muhle, Hiltrud, Wical, Beverly, Finetti, C., Brückner, Reinhard , Pietz, Joachim, Golla, G., Jillella, Dinesh , Linnet, Karen Markussen, Charles, Perrine , Moog, Ute , Õiglane‐Shlik, Eve, Mantovani, John F., Park, Kristen , Deprez, Marie, Lederer, Damien , Mary, Sandrine, Scalais, Emmanuel , Selim, Laila , Coster, Rudy Van , Lagae, Lieven , Nikanorova, Marina , Hjalgrim, Helle , Korenke, Georg-Christoph , Trivisano, Marina , Specchio, Nicola , Ceulemans, Berten , Dorn, Thomas, Helbig, Katherine L. , Hardies, Katia, Stamberger, Hannah , Jonghe, Peter De, Weckhuysen, Sarah , Kluger, Gerhard , Møller, Rikke S. , Wong-Kisiel, Lily, Auvin, Stéphane , Kempen, Marjan J. A. van, Wong‐Kisiel, Lily C. , Maier, Oliver , Lemke, Johannes R. , Krägeloh‐Mann, Ingeborg , Helbig, Ingo , Lerche, Holger , Loddenkemper, Tobias , Villard, Laurent , Rubboli, Guido , Schwarz, Niklas , Specchio, Nicola , Gardella, Elena , Lesca, Gaetan , Møller, Rikke S , Jillella, Dinesh V

Mayo Clinic

Brain | February 23, 2017 | Volume: 140 | Issue: 5 | Pages: 1316-1336

10.1093/brain/awx054 | PMID 28379373 Get It

Epigenetic silencing of the EYA-4 gene in non-Hodgkin’s lymphoma (NHL
Alzein, N. J., Mueller, Melissa D., Deursen, Jan van, Ahlquist, David A. , Molina, Julian R. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 9553-9553

10.1200/jco.2005.23.16_suppl.9553 Get It

Outcome predictors of radical cystectomy in patients with cT 4 prostate cancer: a multi‐institutional study of 62 patients
Spahn, Martin , Morlacco, Alessandro , Boxler, Silvan, Joniau, Steven , Briganti, Alberto , Montorsi, Francesco , Gontero, Paolo , Bader, Pia, Frohneberg, D., Poppel, Hein van, Karnes, R. Jeffrey , Larcher, Alessandro , Karnes, Robert Jeffrey, Poppel, Hein Van, Joniau, Steven , Gontero, Paolo

Mayo Clinic

BJU International | February 21, 2017 | Volume: 120 | Issue: 5B | Pages: No page available

10.1111/bju.13818 | PMID 28220605 Get It

Objectives To identify which patients with macroscopic bladder‐infiltrating T4 prostate cancer ( PC a) might have favourable outcomes when treated with radical cystectomy ( RC ). Materials and Methods We evaluated 62 patients with cT 4cN0–1 cM0 PC a treated with RC and pelvic lymph node dissection between 1972 and 2011. In addition to descriptive statistics, the Kaplan–Meier method and log‐rank tests were used to depict survival rates. Univariate and multivariate Cox regression analysis tested the association between predictors and progression‐free, PC a‐specific and overall survival. Results Of the 62 patients, 19 (30.6%) did not have clinical progression during follow‐up, two (3.2%) had local recurrence, and 32 (51.6%) had haematogenous and nine (14.5%) combined pelvic and distant metastasis. Forty patients (64.5%) died, 34 (54.8%) from PC a and six (9.7%) from other causes. The median (range) survival time of the 19 patients who were metastasis‐free at last follow‐up was 86 (1–314) months, 8/19 patients had a follow‐up of >5 years, and five patients survived metastasis‐free for >15 years. Patients without seminal vesicle invasion ( SVI ) had the best outcomes, with an estimated 10‐year PC a‐specific survival of 75% compared with 24% for patients with SVI . Conclusion For cT 4 PC a RC can be an appropriate treatment for local control and part of a multimodality‐treatment approach. Although recurrences are probable, these do not necessarily translate into cancer‐specific death. Men without SVI had a 75% 10‐year PC a‐specific survival. Although outcomes for patients with SVI are not as favourable, there can be good local control; however, these patients are at higher risk of progression and may need more aggressive systemic treatment.
Chondrocyte Attachment, Proliferation, and Differentiation on Three-Dimensional Polycaprolactone Fumarate Scaffolds
Wagner, Eric R. , Parry, Joshua A. , Dadsetan, Mahrokh, Bravo, Dalibel , Riester, Scott M. , Wijnen, André J. van , Yaszemski, Michael J. , Parry, Joshua, van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | February 18, 2017 | Volume: 23 | Issue: 13-14 | Pages: 622-629

10.1089/ten.tea.2016.0341 | PMID 28375818 Get It

Informal Training Experiences and Explicit Bias against African Americans among Medical Students
Burke, Sara E. , Perry, Sylvia , Cunningham, Brooke A. , Yeazel, Mark W. , Przedworski, Julia , Ryn, Michelle van , Phelan, Sean M. , van Ryn, Michelle, Dovidio, John F. , Burgess, Diana Jill , Hardeman, Rachel R. , Perry, Sylvia P , van Ryn, Michelle

Mayo Clinic

Social Psychology Quarterly | February 16, 2017 | Volume: 80 | Issue: 1 | Pages: 65-84

10.1177/0190272516668166 | PMID 31452559 Get It

Despite the widespread inclusion of diversity-related curricula in U.S. medical training, racial disparities in the quality of care and physician bias in medical treatment persist. The present study examined the effects of both formal and informal experiences on non-African American medical students’ ( N = 2,922) attitudes toward African Americans in a longitudinal study of 49 randomly selected U.S. medical schools. We assessed the effects of experiences related to medical training, accounting for prior experiences and attitudes. Contact with African Americans predicted positive attitudes toward African Americans relative to white people, even beyond the effects of prior attitudes. Furthermore, students who reported having witnessed instructors make negative racial comments or jokes were significantly more willing to express racial bias themselves, even after accounting for the effects of contact. Examining the effects of informal experiences on racial attitudes may help develop a more effective medical training environment and reduce racial disparities in healthcare.